Product nameHuman SDMA ELISA kit
Intra-assay Sample n Mean SD CV% Sample 1 12 0.27µM 7.5% Sample 2 12 0.67µM 4.8% Inter-assay Sample n Mean SD CV% Sample 1 6 0.22µM 6% Sample 2 6 0.63µM 7%
Sample typeSerum, EDTA Plasma
Range0.001 µM - 1.1 µM
Sample specific recovery Sample type Average % Range Spike 101.5 101% - 102%
Assay time21h 00m
Assay durationMultiple steps standard assay
Species reactivityReacts with: Human
The Human SDMA ELISA kit (ab213973) is intended for the quantitative determination of symmetric dimethylarginine (SDMA) in human EDTA-plasma and serum.
This assay is based on the method of competitive enzyme linked immunoassays. The sample preparation includes the addition of a derivatization reagent for SDMA derivatization. Afterwards, the treated samples and the polyclonal SDMA antiserum are incubated in wells of a microtiter plate coated with SDMA derivative (tracer). During the incubation period, the target SDMA in the sample competes with the tracer immobilized on the wall of the microtiter wells for the binding of the polyclonal antibodies. The SDMA in the sample displaces the antibodies out of the binding to the tracer. Therefore the concentration of the tracer-bound antibody is inverse proportional to the SDMA concentration in the sample. During the second incubation step, a peroxidase conjugated antibody is added to each microtiter well to detect the anti-SDMA antibodies. After washing away the unbound components tetramethylbenzidine (TMB) is added as a peroxidase substrate. Finally, the enzymatic reaction is terminated by an acidic stop solution. The color changes from blue to yellow and the absorbance is measured in a photometer at 450 nm. The intensity of the yellow color is inverse proportional to the SDMA concentration in the sample; this means high SDMA concentration in the sample reduces the concentration of tracer-bound antibodies and lowers the photometric signal.
A dose response curve of absorbance unit (optical density, OD at 450 nm) vs. concentration is generated using the values obtained from the standards. SDMA present in the samples is determined directly from this curve.
The dosage of most drugs must be adapted in renal insufficiency, making accurate assessment of renal function a prerequisite in clinical medicine Furthermore, even a modest decline in renal function has been recognized as a cardiovascular risk.
In clinical practice serum creatinine is typically used to asses renal function, but this serum creatinine does not increase at modest decline in renal function. Consequently, there is an ongoing search for suitable endogenous markers of renal function.
SDMA is a methylated derivative of L-Arginine which is strictly eliminated by renal extraction, thus SDMA plasma level is strongly correlated to renal function. In 18 studies with more than 2136 patients systemic SDMA concentrations correlated highly with inuline clearance, as well as with various clearance estimates combined and serum creatinine. With respect to this SDMA exhibits properties of a reliable marker of renal dysfunction.
Moreover, there are hints that increased SDMA correlates with total sequential organ failure indicating both renal and hepatic failure and an increased cardiovascular risk.
- Renal failure
- Cardiovascular risk in renal dysfunction
- Hypertension in renal dysfunction
Tested applicationsSuitable for: Competitive ELISAmore details
PlatformPre-coated microplate (12 x 8 well strips)
Storage instructionsPlease refer to protocols.
Components 1 x 96 tests Conjugate 1 x 12ml Control 1 1 x 500µl Control 2 1 x 500µl Derivatization Reagent 1 x 6ml Reaction Buffer 1 x 15ml SDMA Antibody 1 x 6ml SDMA Coated Microplate (12x 8 well strips) 1 unit Standard 1 (0.0 µM) 1 x 500µl Standard 2 (0.1 µM) 1 x 500µl Standard 3 (0.3 µM) 1 x 500µl Standard 4 (0.6 µM) 1 x 500µl Standard 5 (1.5 µM) 1 x 500µl Standard 6 (4.0 µM) 1 x 500µl Stop Solution 1 x 15ml TMB Substrate 1 x 15ml Wash Buffer Concentrate (10X) 2 x 100ml
- symmetric dimethylarginine
Our Abpromise guarantee covers the use of ab213973 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Competitive ELISA||Use at an assay dependent concentration.|
ab213973 has not yet been referenced specifically in any publications.